Alto Neuroscience vs eGenesis
Side-by-side comparison of AI visibility scores, market position, and capabilities
Nasdaq-listed (ANRO). Raised $120M PIPE (2026) to fund ALTO-207 Phase 2b. FDA Fast Track for ALTO-101. Biomarker-stratified psychiatry matching patients to drugs using brain biology. 4 data readouts through 2027.
About
Alto Neuroscience is a publicly-listed (Nasdaq: ANRO) clinical-stage biotech applying biomarker-stratified patient selection to psychiatry — matching patients to drugs based on brain biology rather than symptom checklists that have historically produced inconsistent treatment outcomes. The company raised a $120 million PIPE in 2026 to fund Phase 2b development of ALTO-207, a fixed-dose combination of pramipexole and ondansetron for treatment-resistant depression (TRD). The FDA has granted Fast Track designation for ALTO-101, and Alto has four clinical data readouts expected through 2027.
FDA-cleared IND for CRISPR-edited pig kidney (ESKD Phase 1/2/3). First patient dialysis-free at 7+ months post-transplant. 69-gene-edited pig — most complex CRISPR ever.
About
eGenesis is developing gene-edited pig organs for human transplantation — xenotransplantation — using a 69-gene CRISPR editing protocol that simultaneously knocks out pig genes that trigger human rejection, adds human immune tolerance genes, and eliminates porcine endogenous retroviruses. The company received FDA clearance for its IND for EIGEN-2784 (a gene-edited pig kidney) for end-stage kidney disease, and its first transplant patient remained dialysis-free at more than 7 months post-transplant — the longest reported survival for a xenotransplantation recipient.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.